US › Healthcare

Pharvaris BV (PHVS)

US · Healthcare · Biotechnology

$33.87+5.02%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-39.8M

Profit YoY

+14.0%

EPS

$-0.71

EPS estimate

$-0.62

EPS came in at -0.71 against a street estimate of -0.62 — a miss of 14.5%.

Key statistics

Market cap

$2.28B

Forward P/E

0.0

P/B

8.39

Book value

$4.12

EPS (TTM)

$-3.12

52-week high

$36.60

52-week low

$19.56

50-day MA

$32.70

200-day MA

$27.96

Beta

-2.34

Analyst view

Analysts rate Pharvaris BV a buy (8 buy, 0 hold, 1 sell out of 9) with an average price target of $47.94.

Shareholding

Insiders

6.13%

Institutions

85.29%

Largest institutional holders

Fund	Stake
General Atlantic Llc	11.49%
FMR Inc	8.99%
Foresite Capital Management IV, LLC	6.84%
venBio Partners LLC	6.64%
Viking Global Investors LP	5.23%
EQT Fund Management S.à r.l.	4.90%
Deerfield Management Co	4.47%
Bain Capital Life Sciences Investors, LLC	3.83%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Pharvaris BV — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.